Valeant Pharmaceuticals Intl Inc Stock Analysis (NYSE:VRX)

Add to My Stocks
$10.86 $0.15 (1.4%) VRX stock closing price Mar 23, 2017 (Closing)
Watch Robo Advisor Video of VRX Stock Analysis
Valeant
Updated on : Mar 23, 2017
previous close
VRX 10.9 (0%)
S&P 500 2346 (0%)
Closing Price On: Mar 23, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$billion
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-5.5%
Sector Average:
-6.4%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Debt/Equity Ratio
Debt:
29.85B
Debt/Equity Ratio:
 9.16
Compared to the industry
Cash Flow
Operating cash flow:
$512.5M
Net Income:
-$514.6M
PROS      CONS
FCF Margin
PE Valuation
PS Valuation
Recent Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
VRX PS :
0.4
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-1.4%
Return on Equity:
-48.7%
Free Cash Flow Margin:
21.9%
Double Tap To Exit Full Screen
0:00
/

Valeant Pharmaceuticals Intl Inc Analysis Video

1134 6 2 1

View Valeant Pharmaceuticals Intl Inc stock analysis video. This is our VRX analyst opinion covering the buy and sell arguments for VRX stock.

Valeant Pharmaceuticals Intl Inc Stock Rating (3/5)

Our Valeant Pharmaceuticals Intl Inc stock opinion is based on fundamentals of the company. This Valeant Pharmaceuticals Intl Inc stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy VRX stock?

  • The price to earnings multiple of 2 is attractive when compared with the industry average PE ratio of 20.8.
  • When compared with the Medical-Drugs industry average PS ratio of 4.6, the price-to-sales ratio of 0.4 for VRX stock is attractive.
  • The company has a healthy free cash flow margin of 21.9%.

Should you sell VRX stock?

  • Valeant revenue saw a decline of -13.8% YoY in 2016 Q4.
  • Over the last twelve months, Valeant posted an average operating loss margin of -5.5%.
  • Valeant posted an average Net loss of -24.9% in the last twelve months.
  • With a debt/equity ratio of  9.16, Valeant is highly leveraged in comparison to Medical peers.
  • Valeant has a negative ROIC (Return on Invested Capital) of -1.4%.
  • Valeant has a negative return on equity of -48.7%. This indicates that the firm is inefficient at generating profits.

Comments on this video and Valeant Pharmaceuticals Intl Inc stock

arnulacroix22 on Valeant Pharmaceuticals Intl Inc stock analysis ($173.26)
bullish
Watch Valeant Pharmaceuticals (VRX) stock @ current levels. The company said that it will acquire Salix Pharmaceuticals for $158.00 per share in cash. Check this out http://drstockpick.com/27356/stock-alert...
reply